keyword
MENU ▼
Read by QxMD icon Read
search

Survivors of Hodgkin's Disease

keyword
https://www.readbyqxmd.com/read/29494295/treating-cardiovascular-complications-of-radiotherapy-a-role-for-new-pharmacotherapies
#1
Nathalie Donis, Cécile Oury, Marie Moonen, Patrizio Lancellotti
Available data indicate that survivors of breast cancer and Hodgkin lymphoma who received mediastinal radiotherapy are at increased risk of developing radiation-induced cardiovascular diseases (RICVD) one or two decades after treatment. Although the risk with modern radiation treatment is likely to be lower in these patient groups, cardiotoxicity is still observed in a subset of patients. In addition, radiation-associated cardiovascular complications can, in the future, extend to other groups of cancer patients who are treated for tumors that are localized near the heart...
March 1, 2018: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29468647/brentuximab-vedotin-prior-to-allogeneic-stem-cell-transplantation-in-hodgkin-lymphoma-a-report-from-the-ebmt-lymphoma-working-party
#2
Ali Bazarbachi, Ariane Boumendil, Hervé Finel, Mohamad Mohty, Luca Castagna, Karl S Peggs, Didier Blaise, Boris Afanasyev, José L Diez-Martin, Jorge Sierra, Adrian Bloor, Carmen Martinez, Stephen Robinson, Ram Malladi, Jean El-Cheikh, Paolo Corradini, Silvia Montoto, Peter Dreger, Anna Sureda
Brentuximab vedotin (BV) is an anti-CD30 antibody-drug conjugate. Preliminary data suggest that BV might improve outcomes after allogeneic stem cell transplantation (SCT) for Hodgkin lymphoma (HL) when used as pre-transplant salvage therapy. Between 2010 and 2014, 428 adult patients underwent an allogeneic SCT for classical HL at participating centres of the European Society for Blood and Marrow Transplantation. We compared the outcomes of 210 patients who received BV prior to allogeneic SCT with that of 218 patients who did not receive BV...
February 22, 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/29427203/cardiovascular-disease-incidence-in-adolescent-and-young-adult-cancer-survivors-a-retrospective-cohort-study
#3
Theresa H M Keegan, Lawrence H Kushi, Qian Li, Ann Brunson, X Chawla, Helen K Chew, Marcio Malogolowkin, Ted Wun
PURPOSE: Few population-based studies have focused on cardiovascular disease (CVD) risk in adolescent and young adult (AYA; 15-39 years) cancer survivors and none have considered whether CVD risk differs by sociodemographic factors. METHODS: Analyses focused on 79,176 AYA patients diagnosed with 14 first primary cancers in 1996-2012 and surviving > 2 years after diagnosis with follow-up through 2014. Data were obtained from the California Cancer Registry and State hospital discharge data...
February 9, 2018: Journal of Cancer Survivorship: Research and Practice
https://www.readbyqxmd.com/read/29417294/a-pilot-investigation-on-impact-of-participation-in-a-long-term-follow-up-clinic-ltfu-on-breast-cancer-and-cardiovascular-screening-among-women-who-received-chest-radiation-for-hodgkin-lymphoma
#4
K Baxstrom, B A Peterson, C Lee, R I Vogel, A H Blaes
BACKGROUND: Women treated with chest radiation for Hodgkin lymphoma (HL) are at significantly increased risk of breast cancer and cardiovascular disease. HL survivors are recommended to have annual dual screening with mammogram (MMG) and breast magnetic resonance imaging (MRI). They are also recommended to undergo echocardiogram (echo) 5 years after completion of radiation. We performed a pilot study to characterize the women who are and are not receiving proper dual screening for breast cancer and baseline echo, and to examine the impact of a LTFU clinic consultation on screening...
February 7, 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29381685/high-burden-of-subsequent-malignant-neoplasms-and-cardiovascular-disease-in-long-term-hodgkin-lymphoma-survivors
#5
Simone de Vries, Michael Schaapveld, Frederika A van Nimwegen, Katarzyna Jóźwiak, Pieternella J Lugtenburg, Laurien A Daniëls, Judith M Roesink, Richard W M van der Maazen, Wouter E M Kok, Berthe M P Aleman, Flora E van Leeuwen
BACKGROUND: Hodgkin lymphoma (HL) patients are at an increased risk of late adverse treatment effects. While published studies focussed on the risk of either subsequent malignant neoplasms (SMNs) or cardiovascular disease (CVD), we examined the combined burden from SMN and CVD. METHODS: In 2908 5-year HL survivors treated between 1965 and 2000, the burden from SMN and/or CVD was assessed using cumulative incidences (CIs) and the mean cumulative count (MCC). RESULTS: We identified 888 SMNs and 1153 CVDs in 1247 patients (median follow-up 22 years)...
January 30, 2018: British Journal of Cancer
https://www.readbyqxmd.com/read/29373361/urgent-chemotherapy-in-sepsis-like-shock-related-to-hematologic-malignancies
#6
Marlène Cherruault, Marielle Le Goff, Jérôme Tamburini, Frédéric Pène
OBJECTIVES: Hematologic malignancies may result in multiple organ involvement including pulmonary and renal dysfunctions, and the less common acute circulatory failure. We herein addressed the outcome of patients with sepsis-like shock related to aggressive hematologic malignancies. DESIGN: A 10-year (2007-2016) monocenter retrospective study. SETTINGS: A medical ICU in a tertiary care center. PATIENTS: Patients with circulatory shock requiring vasopressors and who subsequently received chemotherapy...
January 25, 2018: Critical Care Medicine
https://www.readbyqxmd.com/read/29289336/-hodgkin-lymphoma-current-and-future-therapeutic-strategies
#7
REVIEW
Anthony Turpin, Jean-Marie Michot, Emmanuelle Kempf, Renaud Mazeron, Peggy Dartigues, Marie Terroir, Angela Boros, Serge Bonnetier, Cristina Castilla-Llorente, Tereza Coman, Alina Danu, David Ghez, Sylvain Pilorge, Julia Arfi-Rouche, Laurent Dercle, Jean-Charles Soria, Patrice Carde, Vincent Ribrag, Christophe Fermé, Julien Lazarovici
Hodgkin lymphoma (HL) is a cancer that mostly affects young people, in which modern therapeutic strategies using chemotherapy and radiotherapy result in a cure rate exceeding 80%. Survivors are exposed to long-term consequences of treatments, such as secondary malignancies and cardiovascular diseases, whose mortality exceeds the one of the disease itself, with long-term follow-up. The current therapeutic strategy in HL, based on the assessment of initial risk factors, is the result of large clinical trials led by the main international cooperating groups...
January 2018: Bulletin du Cancer
https://www.readbyqxmd.com/read/29192533/cardiovascular-mortality-trends-in-non-hodgkin-s-lymphoma-a-population-based-cohort-study
#8
Mohamed Gomaa Kamel, Amr Ehab El-Qushayri, Tran Quang Thach, Nguyen Tien Huy
BACKGROUND: Non-Hodgkin's lymphoma (NHL) survivors are at a higher risk of cardiovascular diseases (CVDs). METHODS: A population-based study was conducted to investigate the cardiovascular mortality trends to identify NHL survivors at the highest risk. RESULTS: The CVDs mortality was the second most common cause of death (13.07%) after NHL. There were more patients ≥ 60 years old in the cardiovascular group (87.2%), P < 0.001. Patients who died from CVDs had the best survival while patients who died from NHL had a significantly lower mean survival...
January 2018: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/29128555/combined-haploidentical-and-umbilical-cord-blood-allogeneic-stem-cell-transplantation-for-high-risk-lymphoma-and-chronic-lymphoblastic-leukemia
#9
Jingmei Hsu, Andrew Artz, Sebastian A Mayer, Danielle Guarner, Michael R Bishop, Ronit Reich-Slotky, Sonali M Smith, June Greenberg, Justin Kline, Rosanna Ferrante, Adrienne A Phillips, Usama Gergis, Hongtao Liu, Wendy Stock, Melissa Cushing, Tsiporah B Shore, Koen van Besien
Limited studies have reported on outcomes for lymphoid malignancy patients receiving alternative donor allogeneic stem cell transplants. We have previously described combining CD34-selected haploidentical grafts with umbilical cord blood (haplo-cord) to accelerate neutrophil and platelet engraftment. Here, we examine the outcome of patients with lymphoid malignancies undergoing haplo-cord transplantation at the University of Chicago and Weill Cornell Medical College. We analyzed 42 lymphoma and chronic lymphoblastic leukemia (CLL) patients who underwent haplo-cord allogeneic stem cell transplantation...
February 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29041005/cardiogenic-shock-during-first-infusion-of-anthracycline-chemotherapy-in-a-patient-with-hodgkin-lymphoma-an-unusual-event
#10
Giulio Binaghi, Damiana Congia, Stefano Cossa, Stefania Massidda, Daniele Pasqualucci, Federica Pilo, Emanuela Serra, Emanuele Angelucci, Maurizio Porcu
INTRODUCTION: Hodgkin lymphoma (HL) is one of the most common types of cancers of the lymphatic system. The currently available therapies enable a cure in approximately 80-85% of treated patients. However, the cardiotoxicity of HL treatment has become a major cause of morbidity and mortality in survivors mainly related to the use of anthracycline. CASE REPORT: An HL, staged IIIB, was diagnosed in a 60-year-old man with no cardiovascular disease. During the first cycle of ABVD chemotherapy (Adriamycin; bleomycin; vinblastine; dacarbazine), near the end of the dacarbazine infusion, the patient presented a sudden cardiogenic shock characterized by a severe left ventricular systolic dysfunction...
October 18, 2017: Cardiology
https://www.readbyqxmd.com/read/28987749/different-manifestation-of-irradiation-induced-coronary-artery-disease-detected-with-coronary-computed-tomography-compared-with-matched-non-irradiated-controls
#11
Alexander R van Rosendael, Laurien A Daniëls, Aukelien C Dimitriu-Leen, Jeff M Smit, Philippe J van Rosendael, Martin J Schalij, Jeroen J Bax, Arthur J H A Scholte
BACKGROUND AND PURPOSE: Patients who received chest irradiation for treatment of a malignancy are at increased risk for the development of coronary artery atherosclerosis. Little is known about the anatomical coronary artery plaque characteristics of irradiation induced coronary artery disease (CAD). This study aimed to evaluate potential differences in the presence, extent, severity, composition and location of CAD in patients treated with mediastinal irradiation compared with non-irradiated controls matched on age, gender and cardiovascular risk factors...
October 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/28927453/employment-status-and-health-related-quality-of-life-among-hodgkin-lymphoma-survivors-results-based-on-data-from-a-major-treatment-center-in-hungary
#12
Ferenc Magyari, Karolina Kósa, Roland Berecz, Anna Illés, Zsófia Miltényi, Zsófia Simon, Árpád Illés
BACKGROUND: Due to risk and response adapted treatment strategies, more than 80% of newly diagnosed classical Hodgkin lymphoma (HL) patients can be cured, and become long-term survivors. However, a high proportion of survivors suffer from treatment-related long-term side effects such as secondary malignancy, organ failure, persistent fatigue and psychological distress. The aim of this study was to evaluate psychological distress and its risk factors among our HL survivors. METHODS: One hundred sixty-three (50% female) adult HL survivors were contacted between January 1, 2012 and march 31, 2015 in our outpatient centre...
September 19, 2017: Health and Quality of Life Outcomes
https://www.readbyqxmd.com/read/28922087/preexisting-cardiovascular-risk-and-subsequent-heart-failure-among-non-hodgkin-lymphoma-survivors
#13
Talya Salz, Emily C Zabor, Peter de Nully Brown, Susanne Oksberg Dalton, Nirupa J Raghunathan, Matthew J Matasar, Richard Steingart, Andrew J Vickers, Peter Svenssen Munksgaard, Kevin C Oeffinger, Christoffer Johansen
Purpose The use of anthracycline chemotherapy is associated with heart failure (HF) among survivors of non-Hodgkin lymphoma (NHL). We aimed to understand the contribution of preexisting cardiovascular risk factors to HF risk among NHL survivors. Methods Using Danish registries, we identified adults diagnosed with aggressive NHL from 2000 to 2010 and sex- and age-matched general-population controls. We assessed HF from 9 months after diagnosis through 2012. We used Cox regression analysis to assess differences in risk for HF between survivors and general population controls...
December 1, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28853979/the-effect-of-atorvastatin-on-vascular-function-and-structure-in-young-adult-survivors-of-childhood-cancer-a-randomized-placebo-controlled-pilot-clinical-trial
#14
Kara L Marlatt, Julia Steinberger, Kyle D Rudser, Donald R Dengel, Karim T Sadak, Jill L Lee, Anne H Blaes, Daniel A Duprez, Joanna L Perkins, Julie A Ross, Aaron S Kelly
PURPOSE: Many adult survivors of childhood cancer are at high-risk of developing cardiovascular disease. Cancer therapy may cause damage to the vascular endothelium, thereby initiating atherosclerosis. Atorvastatin has been shown to improve endothelial function independent of reducing cholesterol, as well as reduce/slow arterial stiffness and thickening, yet has never been studied in childhood cancer survivors (CCS). METHODS: Twenty-seven young adult (age 26.8 ± 6...
August 30, 2017: Journal of Adolescent and Young Adult Oncology
https://www.readbyqxmd.com/read/28846465/post-transplantation-cyclophosphamide-based-haploidentical-transplantation-as-alternative-to-matched-sibling-or-unrelated-donor-transplantation-for-hodgkin-lymphoma-a-registry-study-of-the-lymphoma-working-party-of-the-european-society-for-blood-and-marrow
#15
Carmen Martínez, Jorge Gayoso, Carmen Canals, Hervé Finel, Karl Peggs, Alida Dominietto, Luca Castagna, Boris Afanasyev, Stephen Robinson, Didier Blaise, Paolo Corradini, Maija Itälä-Remes, Arancha Bermúdez, Edouard Forcade, Domenico Russo, Michael Potter, Grant McQuaker, Ibrahim Yakoub-Agha, Christof Scheid, Adrian Bloor, Silvia Montoto, Peter Dreger, Anna Sureda
Purpose To compare the outcome of patients with Hodgkin lymphoma who received post-transplantation cyclophosphamide-based haploidentical (HAPLO) allogeneic hematopoietic cell transplantation with the outcome of patients who received conventional HLA-matched sibling donor (SIB) and HLA-matched unrelated donor (MUD). Patients and Methods We retrospectively evaluated 709 adult patients with Hodgkin lymphoma who were registered in the European Society for Blood and Marrow Transplantation database who received HAPLO (n = 98), SIB (n = 338), or MUD (n = 273) transplantation...
October 20, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28708228/clinical-and-subclinical-cardiac-late-effects-in-pediatric-hodgkin-s-lymphoma-survivors
#16
Carlo Materazzo, Maura Massimino, Elisabetta Schiavello, Marta Podda, Lorenza Gandola, Graziella Cefalo, Serena Catania, Cristina Meazza, Ivan Moschetti, Monica Terenziani
PURPOSE: Cardiac late effects are responsible for a significant burden of mortality and morbidity among pediatric Hodgkin's lymphoma (HL) survivors (HLS). The aim of our study was to assess clinical and subclinical cardiac sequelae in a cohort of childhood HLS treated in the 1980s with doxorubicin, bleomycin, vinblastine, and dacarbazine (the ABVD regimen) and limited-field radiotherapy (RT). METHODS: We retrospectively examined a series of HLS treated from 1979 to 1989...
November 23, 2017: Tumori
https://www.readbyqxmd.com/read/28618843/risk-of-cardiac-death-among-cancer-survivors-in-the-united-states-a-seer-database-analysis
#17
Omar Abdel-Rahman
BACKGROUND: Population-based data on the risk of cardiac death among cancer survivors are needed. This scenario was evaluated in cancer survivors (>5 years) registered within the Surveillance, Epidemiology and End Results (SEER) database. METHODS: The SEER database was queried using SEER*Stat to determine the frequency of cardiac death compared to other causes of death; and to determine heart disease-specific and cancer-specific survival rates in survivors of each of the 10 most common cancers in men and women in the SEER database...
September 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28606176/rituximab-containing-reduced-intensity-conditioning-improves-progression-free-survival-following-allogeneic-transplantation-in-b-cell-non-hodgkin-lymphoma
#18
Narendranath Epperla, Kwang Woo Ahn, Sairah Ahmed, Madan Jagasia, Alyssa DiGilio, Steven M Devine, Samantha Jaglowski, Vanessa Kennedy, Andrew R Rezvani, Sonali M Smith, Anna Sureda, Timothy S Fenske, Mohamed A Kharfan-Dabaja, Phillipe Armand, Mehdi Hamadani
BACKGROUND: In B cell non-Hodgkin lymphoma (B-NHL), rituximab-containing reduced-intensity conditioning regimens (R-RIC) have been shown to provide favorable outcomes in single-arm studies; however, large multicenter studies comparing R-RIC and non-rituximab-containing reduced-intensity conditioning regimens (nonR-RIC) have not been performed. Using the CIBMTR database, we report the outcomes of R-RIC versus nonR-RIC regimens in B-NHL. METHODS: We evaluated 1401 adult B-NHL patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) who received nonR-RIC (n = 1022) or R-RIC (n = 379) regimens...
June 12, 2017: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/28505658/web-exclusives-annals-consult-guys-the-adult-survivor-of-hodgkin-disease-falling-through-the-cracks
#19
Geno J Merli, Howard H Weitz
No abstract text is available yet for this article.
May 16, 2017: Annals of Internal Medicine
https://www.readbyqxmd.com/read/28502334/ap-1-expression-and-its-clinical-relevance-in-immune-disorders-and-cancer
#20
REVIEW
Shivtia Trop-Steinberg, Yehudit Azar
The inflammatory response is known to have a significant role in certain autoimmune diseases and malignancies. We review current knowledge regarding the functions of activator protein 1 (AP-1) as an important modulator in several immune disorders and carcinomas. AP-1 is overexpressed in rheumatoid arthritis and in long-term allogeneic hematopoietic stem cell transplantation survivors; however, decreased expression of AP-1 has been observed in psoriasis, systematic lupus erythematosus and in patients who do not survive after hematopoietic stem cell transplantation...
May 2017: American Journal of the Medical Sciences
keyword
keyword
71874
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"